Skip to content

IRulya Therapeutics Inc.

Public company
Headquarters
NEW HAVEN, Connecticut
Industry
Biotechnology
Ticker
IRLA
CIK
0001662774

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

14
7 appointments, 7 departures

Last event

Oct 9, 2026
Executive departureCEO departs: Dirk Thye, M.D.

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
CEODirk Thye, M.D.Oct 9, 2026Departed
COOBrendan HannahOct 9, 2026Departed
CFOJohn Militello, CPAOct 9, 2026Appointed
directorJune BrayOct 9, 2026Departed
Class I director and as a member of the Audit Committee and Compensation CommitteeCatherine M. BonuccelliOct 9, 2026Appointed
Class III director and as chair of the Audit Committee and as chair of the Compensation CommitteeLeone PattersonOct 9, 2026Appointed
Class I director and as a member of the Audit Committee and as chair of the Nominating and Corporate Governance CommitteeJames ValentineOct 9, 2026Appointed
Class II director and as a member of the Nominating and Corporate Governance CommitteeDrayton WiseOct 9, 2026Appointed
PresidentCharles RyanSep 14, 2026Departed

Related companies

Same industry and state, with recent events.

  1. Executive departure

    CEO departs: Dirk Thye, M.D.

    Dirk Thye, M.D., Chief Executive Officer of IRulya Therapeutics Inc., resigns the role, effective October 8, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Executive Officer

    Source: SEC 8-K, filed Oct 9, 2026

  2. Executive departure

    COO departs: Brendan Hannah

    Brendan Hannah, Chief Operating Officer of IRulya Therapeutics Inc., resigns the role, effective October 8, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Operating Officer

    Source: SEC 8-K, filed Oct 9, 2026

  3. Executive appointment

    CEO appointed: Brigette Roberts, M.D.

    Brigette Roberts, M.D. was named Chief Executive Officer of IRulya Therapeutics Inc., effective October 8, 2026. Brigette Roberts, M.D. succeeds Thye. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Executive Officer

    Source: SEC 8-K, filed Oct 9, 2026

  4. Executive appointment

    CFO appointed: John Militello, CPA

    John Militello, CPA was named Chief Financial Officer of IRulya Therapeutics Inc., effective October 8, 2026. John Militello, CPA succeeds Hannah. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer

    Source: SEC 8-K, filed Oct 9, 2026

  5. Executive appointment

    COO appointed: Keith Fandrick

    Keith Fandrick was named Chief Operating Officer of IRulya Therapeutics Inc., effective October 8, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Operating Officer

    Source: SEC 8-K, filed Oct 9, 2026

  6. Executive departure

    director departs: June Bray

    June Bray, director of IRulya Therapeutics Inc., resigns the role, effective October 8, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Oct 9, 2026

  7. Executive departure

    director departs: David Lamond

    David Lamond, director of IRulya Therapeutics Inc., resigns the role, effective October 8, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Oct 9, 2026

  8. Executive departure

    director departs: Christopher Senner

    Christopher Senner, director of IRulya Therapeutics Inc., resigns the role, effective October 8, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: director

    Source: SEC 8-K, filed Oct 9, 2026

Last verified Nov 8, 2026